Companies: 10,795·Total market cap: $144.5T
Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

MAZENASDAQHealthcare● Active
$23.97
$-0.30(-1.24%)
Market Cap$1.3B
P/E Ratio
52W High$53.65
52W Low$9.83
Overview

Maze Therapeutics, Inc. (MAZE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · MAZE · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.75maze eps ttm · maze earnings per shareEarnings history
PE Ratio (TTM)maze pe ratio ttm · maze price to earningsPE Ratio deep dive
Revenue (TTM)$20.0Mmaze revenue ttm · maze annual revenueFull revenue history
Dividend YieldNo Dividenddoes maze pay dividends · maze dividend yieldDividend history
Shares Outstanding43.0Mmaze shares outstanding · maze floatShares outstanding history
Next EarningsAug 11, 2026Est.maze earnings date · maze next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00▼ 100.00% YoY
202320242025
maze therapeutics, inc. revenue · maze revenue 2025
FY 2025Net Income-$131.1M▼ 351.04% YoY
202320242025
maze therapeutics, inc. net income · maze profit 2025
FY 2025EPS$-3.05▼ 4020.31% YoY
202320242025
maze eps · maze therapeutics, inc. earnings per share 2025
TTM:Revenue: $20.0MNet Income: -$122.5MEPS: $-2.75View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy6 analystsis maze a buy · maze analyst rating
Strong Buy
0
Buy
6
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$46.00Low
$23.97Current
$63.25Avg Target163.87% upside
$97.00High
maze price target · maze 12 month forecast

Total: 6 · Buy rate: 100.0%

The MAZE analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $63.25, representing +163.87% upside from the current price of $23.97.

Stock Performance

Full History
1D-0.91%
1W-0.82%
1M-7.61%
3M-46.35%
YTD-41.95%
1Y+87.74%
5Y+50.78%

About Maze Therapeutics, Inc.

CEOJason V. Coloma
IPO DateJan 31, 2025
Employees125
CountryUS
Websitemazetx.com

Maze Therapeutics, Inc. a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in …

what is maze therapeutics, inc. · maze stock overview · maze therapeutics, inc. company profile · who is maze therapeutics, inc. ceo · maze NASDAQ · maze therapeutics, inc. headquarters · maze therapeutics, inc. business segments

About Stock Overview & Key Data

Maze Therapeutics, Inc. (MAZE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 31, 2025. As of the latest trading session, MAZE stock price is $23.97, with a market capitalization of $1.3B. The stock has returned +87.74% over the past 12 months and -41.95% year-to-date.

According to 6 Wall Street analysts, the consensus rating for Maze Therapeutics, Inc. stock is Buy, with an average 12-month price target of $63.25. In fiscal year 2025, Maze Therapeutics, Inc. reported revenue of — and net income of -$131.1M. For detailed data — including Maze Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Maze Therapeutics, Inc. (MAZE) stock price is $23.97. The stock is traded on NASDAQ under the ticker symbol MAZE. The 52-week range is $9.83 – $53.65.

MAZE stock priceMAZE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice